Piezo‐assisted ICSI improves fertilization and blastocyst development rates compared with conventional ICSI in women aged more than 35 years
Kohyu Furuhashi, Yoshimi Saeki, Noritoshi Enatsu and 6 more
Reproductive Medicine and Biology · 2019
doi:10.1002/rmb2.12290 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
Purpose Piezo‐assisted intracytoplasmic sperm injection (Piezo‐ICSI) is reported to be an effective method for inseminating fragile oocytes compared with conventional ICSI (c‐ICSI). However, infertile patient groups suitable for Piezo‐ICSI have not been elucidated. This study was conducted to determine age groups suitable for Piezo‐ICSI using sibling egg controls inseminated by a well‐trained embryologist to reduce technical inequalities. Methods A total of 947 matured oocytes were inseminated either by Piezo‐ICSI or by c‐ICSI in sibling oocytes as controls. Fertilization (2 pronuclei, PN), survival, and blastocyst development rates on day (D) 5 and D6 after insemination were compared between the Piezo‐ICSI and c‐ICSI groups. Further analyses were applied to groups of women > 35 or ≤35 years of age. Results There were no significant differences in fertilization, survival, or blastocyst development rates between the two insemination treatment groups. However, for women > 35 years of age, the fertilization ( P = .008) and blastocyst development ( P = .016) rates with Piezo‐ICSI on D5 and D6 were significantly higher than in those subjected to c‐ICSI. Conclusions Piezo‐ICSI was useful for inseminating oocytes from women >35 years of age.
Abstract licence: CC BY-NC-ND
References19
19 more references, whose wording the paper’s licence keeps private.
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.